[2014/11/19] InnoPharmax Selected for Poster Presentation on Gemcitabine HCl Oral Formulation (D07001-F4) at 26th ENA
InnoPharmax Selected for Poster Presentation on Gemcitabine HCl Oral Formulation (D07001-F4) at 26th ENA



Taipei, Taiwan, R.O.C. – InnoPharmax Inc. announced that the Company's phase 1 study on Gemcitabine HCl Oral Formulation (D07001-F4) has been selected for poster presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (“ENA”).  The 26th ENA is being held in Barcelona, Spain from Nov. 18 - 21, 2014. 

The Company's abstract titled, “Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.,” will be part of the poster session on "Cytotoxics " (Poster Board Number 028) which is scheduled on 19 November 2014. The authors of the poster presentation include clinical physicians and staff involved in the study from National Taiwan University Hospital and National
Cheng Kung University Hospital, along with InnoPharmax colleagues.

“After the poster presentation at 2014 ASCO meeting, we are pleased to be selected to present our preliminary research data on D07001-F4 by ENA 2014 Executive Scientific Committee at 26th ENA” commented Dr. CS Hsu, President of InnoPharmax. 

About Gemcitabine Hydrochloride Oral Formulation (D07001-F4)
Gemcitaine (2',2'-difluorodeoxycytidine) is a fluorine-substituted deoxycytidine analog with a broad spectrum of antitumor activity.  It is rapidly and extensively deaminated by cytidine deaminase to the inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU).  It has been reported in a reported clinical study that the systemic exposure to oral gemcitabine was low due to extensive firstpass metabolism to dFdU. 
D07001-F4 was developed based on InnoPharmax's proprietary formulations to overcome the problem of low bioavailability of oral gemcitabine. In dog pharmacokinetic study, gemcitabine was well absorbed from the D07001-F4 formulation with oral bioavailability over 70%. Preclinical studies have shown that D07001-F4 shows efficacy in pancreatic as well as other selected tumor models.

About InnoPharmax
InnoPharmax is a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology and oncology. It develops and acquires potential drug candidates for further development as well as commercialization, and uses internally developed drug delivery technology platforms for improving the safety and effectiveness of currently available drugs to provide better medical choices in these specific disease categories.
回上頁

優吉兒網站設計 - Website Info.